STERIS to buy surgical safety firm Xodus Medical for $2.1B
What's the deal? STERISDealroom has a profile for this one. Try Dealroom → has signed a definitive agreement to acquire Xodus MedicalDealroom has a profile for this one. Try Dealroom →, a Pennsylvania-based specialty surgical products business, for $2.1 billion at closing. The all-equity deal is expected to close by December 31, 2026, subject to regulatory approvals.
Who's involved? Dublin-based STERIS is a global provider of infection-prevention products and services. Founded in 1993 near Pittsburgh, Xodus Medical makes surgical safety devices, including its flagship Pink Pad patient positioning systems, for hospitals worldwide.
What's the endgame? STERIS is adding consumables used in the operating room to its healthcare portfolio. "Xodus Medical's product portfolio complements and expands STERIS's offering," said chief executive officer Dan Carestio, noting the business has grown "at double-digit rates."
By the numbers: Xodus Medical is expected to post roughly $245 million in revenue and about $135 million in adjusted EBIT for calendar 2026. STERIS anticipates cash tax benefits with a net present value of about $300 million, cutting the net purchase price to roughly $1.8 billion.
The terms: STERIS Corporation will acquire all of Xodus Medical's equity, financing the deal primarily with debt. The price is subject to customary adjustments, plus potential earnout consideration of up to $150 million tied to performance targets in calendar 2028.
Why now? STERIS says the acquisition will be accretive to top-line growth, margins, and adjusted earnings. The company plans to provide a revised fiscal 2027 outlook including Xodus Medical after the deal closes.
The signal: The deal reflects continued consolidation among healthcare suppliers, as larger players bolt on specialty consumables businesses with recurring revenue and double-digit growth to strengthen their operating-room franchises.
Read more: AP News
Image credit: Ruhrfisch
